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Abstract: This paper reviews the current data on the use of the first approved intravenous
ibuprofen product for the management of post-operative pain and fever in the United States.
The management of acute and post-operative pain and fever with nonsteroidal anti-inflammatory
agents (NSAIDs) is well documented. A search in Medline and International Pharmaceutical
Abstracts of articles until the end of November 2009 and references of all citations were conducted. Available manufacturer data on file were also analyzed for this report. Several randomized
controlled studies have demonstrated the opioid-sparing and analgesic effects of 400 and 800 mg
doses of intravenous ibuprofen in a series of post-operative patient populations. Two recent studies
have also noted the improvement in fever curves in critically ill and burn patients. These data,
along with pharmacokinetic and pharmacologic properties, are explored in this review, which
addresses the clinical utility of a parenteral NSAID in a hospitalized patient for post-operative
pain management and fever reduction. Further data on intravenous ibuprofen are needed to define
long-term utilization, management of acute pain, and use in special populations.
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Acute pain is a significant problem for inpatients and can occur secondary to acute
illness or disease processes, trauma, or operative procedures. In the post-operative
period, 80% of individuals suffer from post-operative pain with almost all describing
it as moderate to severe.1 Physiologically, pain serves to alert individuals to tissue
damage and to prevent further harm. However, in the acute inpatient setting, it often
serves no useful purpose. Pain activates the sympathetic nervous system, increasing
blood pressure, cardiac workload and respiratory rate.2 It impairs recovery by reducing
mobility and physical activity. Despite the use of medications to control pain, it often
remains undertreated and is a problem in hospitals and long-term care facilities.
Opioid analgesics are a mainstay in the management post-operative and acute pain
in the inpatient setting.3 However, their use is often limited by adverse effects including
respiratory depression, sedation, allergic reactions, and gastrointestinal events. Opioids
are useful in mitigating the sensation of pain, but provide no benefits to the underlying
disease process. Adjunctive agents for pain including non-steroidal anti-inflammatory
agents (NSAIDs) may be used in combination with opioids. Combination therapy may
help mitigate the side effects of both agents by reducing the total dose required. The
anti-inflammatory properties of NSAIDs may also be useful in promoting healing
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and resolution of pain. NSAIDs inhibit the production of
cyclooxygenase (COX)-1 and COX-2 enzymes and prevent
the sensitization of pain receptors at the site of injury. The
American Pain Society advocates the use of combination
therapy including NSAIDs, for optimal pain control.4 The
World Health Organization (WHO) includes NSAIDs in
step 1 of the analgesic ladder for the treatment of mild to
moderate pain.5 They are also included as adjuncts in the
treatment of persistent and moderate to severe pain in steps
2 and 3, respectively.
Recent data on the safety of COX-2 selective agents and
fraudulent data in previously published pain studies have
created significant clinical questions for clinicians. NSAIDs,
particular COX-2 selective agents, have received great criticism
related to an increased risk of cardiovascular events, including
acute myocardial infarction, stroke, and coronary heart disease
death.6–8 As a result, many agents were removed from the
market worldwide. Likewise, information on the publication of
fraudulent data has led to the retraction of a significant number
of papers on the safety and efficacy of both COX-2 selective
agents and NSAIDs in the post-operative setting.9 These
significant controversies create a need for additional research
in the field and for new products and formulations.
The antipyretic effects of NSAIDs are also well documented, resulting from inhibition of COX-1 to block the
conversion of arachidonic acid to prostaglandins such as
PGE2 in the immune response pathway.10 Fever is common
in hospitalized patients and can be a result of infection,
thrombosis, autoimmune disorders, malignancies, drugs, or
other unknown causes.11 Reduction of fever not only offers
substantial benefit to a patient’s well-being but the metabolic
compromise of sustained fever may potentiate risks associated with common co-morbidities encountered in hospitalized patients. Ibuprofen has been a primary agent of choice,
along with acetaminophen, in the reduction of fever in both
adults and children. Data have demonstrated equal efficacy
between the two and offered pharmacokinetic advantages of
ibuprofen in early onset and durable antipyretic effects after
therapeutic concentrations have waned.12,13
Until recently, ketorolac (Toradol®; Roche Laboratories,
Nutley, NJ, USA) was the only NSAID available in parenteral
form in the United States (US), and while it possesses known
antipyretic effects, it is most frequently used in the management of acute and post-operative pain. Its use is limited by
side effects that prohibit more than 5 days of therapy.14 Many
practitioners also have the perception that it is more effective
than oral ibuprofen.15 However, a review of studies examining both parenteral ketorolac and oral ibuprofen found that
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oral ibuprofen is as effective as ketorolac in the management
of pain in emergency department patients. The authors also
point out that the cost of oral ibuprofen is significantly less
than parenteral ketorolac. Additional parenteral options
are available outside the US where approved. Tenoxicam
(Mobiflex®; Roche Laboratories, United Kingdom) is an
intravenous NSAID available in the United Kingdom.16
Parecoxib (Dynastat®; European Union) is the first COX-2
inhibitor available for parenteral administration and is
approved through much of Europe for short-term perioperative pain control much in the same way ketorolac (Toradol®)
is used in the US.17 Two formulations of injectable diclofenac
are available (Dyloject®; Javelin Pharmaceuticals, United
Kingdom and Voltarol®; Novartis, United Kingdom). Dyloject® is a novel injectable diclofenac formulation employing
polyethylene glycol and benzyl alcohol as excipients, and is
marketed in Europe and requires specific reconstitution slow
infusion to minimize venous irritation.18 These products are
not discussed further as a part of this review.
Oral ibuprofen is a commonly used NSAID with antipyretic, anti-inflammatory, and analgesic properties. It is
a mainstay in the treatment of acute pain and fever and
is readily available over the counter. Mechanistically, it
acts both centrally and peripherally to reduce pain and
fever. However, the use of ibuprofen in the inpatient or
post-operative setting has previously been limited by the
lack of a commercially available parenteral formulation.
The drug’s lipophilic properties have rendered production
into an intravenous formulation difficult, but an intravenous
form of ibuprofen (Caldolor®; Cumberland Pharmaceuticals,
Nashville, TN, USA) has recently been approved for use in
the US. Previously, ibuprofen was available in a parenteral
form as a lysine salt (Neoprofen®) and an intravenous solution (Pedea®) only for treatment of patent ductus arteriosus in
the neonatal population.19,20 Studies found that intravenous
ibuprofen use improved pain control and reduced opioid use
in the orthopedic and abdominal surgery setting as well as
on fever reduction in the critically ill population. Its impact
on pain management in the acute and post-operative settings,
as well as long-term use remains undefined.

Methods
We conducted a Medline search for all articles published until
the end of November 2009 using the MeSH terms “intravenous” and “ibuprofen”. Additional searches of International
Pharmaceutical Abstracts and EMBASE were conducted
using the search terms “intravenous ibuprofen”. Articles
on the use of intravenous ibuprofen for indications other
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than pain management, including patent ductus arteriosus,
and hypoxic ischemic encephalopathy, ibuprofen lysine,
Pedea®, and animal data, were excluded. Reference lists from
retrieved articles were also searched for additional relevant
citations. Meeting abstracts were searched for pertinent citations. Unpublished data were also obtained by special request
from Cumberland Pharmaceuticals (Nashville, TN, USA).

Pharmacology
Mechanism of action
The mechanism of action and pharmacology of intravenous
ibuprofen does not differ from the mechanism of oral ibuprofen. It works through reversible inhibition of COX-1 and
COX-2 enzymes to decrease the conversion of arachidonic
acid into prostaglandin endoperoxides including thromboxane and prostacyclin.21
The separation of functions of COX-1 and COX-2 is
not straightforward, and a mixture of their activity is frequently responsible for the therapeutic and adverse effects
of NSAIDs, including ibuprofen.21,22 COX-2 is produced in
response to tissue injury, growth factors, tumor promoters
and cytokines.21 COX-1 is found in most cells and maintains
many physiologic housekeeping functions. Inhibition of
prostaglandin E2 (PGE2) is responsible for the anti-pyretic
properties of NSAIDs. The pain-relieving properties of
NSAIDs relate to the inhibition of PGE2 and its effects peripherally and centrally. COX-1 and COX-2 in the spinal cord
are released in response to painful peripheral stimuli to form
prostaglandins which sensitizes peripheral nerve endings.
Inhibition desensitizes the painful response. Centrally, inhibition of these enzymes in the spinal cord blunts the central
sensitization and increase in excitability of spinal dorsal horn
neurons seen in response to painful stimuli. Prostaglandins
PGE2 and PGI2 are responsible for inflammation including
edema formation and leucocyte infiltration through promotion of blood flow. Inhibition by COX enzymes reduces
edema and suppresses the immunologic response associated
with inflammation.
Interestingly, in animal models inhibition of COX
enzymes prior to the onset of sepsis mitigated the physiologic abnormalities seen in sepsis and reduced mortality.23
In addition, a randomized controlled trial of ibuprofen in
sepsis demonstrated an improvement in organ dysfunction in
patients with hypothermia, but did not improve survival.24

Adverse events
It is this enzymatic inhibition of COX-1 and COX-2 that also
leads to the hematologic, renal, and gastrointestinal adverse
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events associated with NSAIDs.21,22 Other side effects are
idiosyncratic and less directly related to COX inhibition.
COX-1 is responsible for the production of thromboxane
A2, which is expressed in mature platelets. Thromboxane
A2 acts as a platelet aggregator and enhances the effect of
other platelet aggregators, including thrombin. While aspirin
acts as an irreversible inhibitor of COX-1 and thromboxane
A2 production in a dose-dependent manner, the activity of
NSAIDs on platelets is temporary and reversible. It is incomplete inhibition of platelet aggregation that is believed to lead
to the increased incidence of thrombotic adverse events with
NSAIDs, including ibuprofen.21
Within the kidney, COX enzymes synthesize prostaglandins in the medulla and cortex. They play a key role in blood
pressure regulation and maintenance of renal blood flow,
especially in patients with long-standing chronic kidney
disease or who are volume depleted.22 These effects are what
often lead to the hypertension seen with NSAID therapy. The
vasodilatory effects of prostaglandins and COX enzymes
maintain renal blood flow and glomerular filtration, and
inhibition of their production leads to decreased perfusion
and a decline in renal function.
Synthesis of PGE2 is cytoprotective within the gastrointestinal (GI) tract and is protective against peptic ulcers, even
without a reduction in acid secretion.21 Inhibition of COX-1
is thought to be responsible for the increased incidence of
peptic ulcers and GI bleeding seen with NSAID therapy.
Ibuprofen is non-selective, and its inhibition of COX-1 and
COX-2 means that it is prone to GI side effects.
Bronchospasm can also be observed with NSAID therapy
and is more prevalent in patients with a history of asthma or
reactive airway disease.21 Inhibition of the COX enzymes
by NSAIDs shifts metabolism of arachidonic acid from
PGE2 and PGI2, which relax bronchial smooth muscle.22
Arachidonic acid instead is synthesized into leukotrienes
that constrict airway smooth muscle.

Drug interactions
Like oral ibuprofen, the intravenous formulation interacts
with several medications by either reducing protein binding,
causing additive side effects, or inhibiting renal prostaglandin
synthesis. Aspirin, the first and prototypical NSAID, has a
similar mechanism of action and side effect profile as intravenous ibuprofen. When taken concomitantly, the protein
binding of ibuprofen is reduced while the clearance of free
ibuprofen is unchanged, although the effect of this interaction is unknown.25 The administration of aspirin or any other
NSAID is not recommended in combination with intravenous
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ibuprofen due to additive COX inhibition and thus additional
side effects. Concomitant administration of an NSAID with
anticoagulants including warfarin and heparin products may
also contribute to additional side effects including the risk
of gastrointestinal bleeding.25 Patients who frequently use
dual NSAID therapy have a higher risk of GI bleeding than
users of either drug alone. In the elderly population, the risk
of GI bleeding is higher and the interaction of these agents
could be fatal.
NSAIDS when used in combination with angiotensin converting enzyme (ACE) inhibitors inhibit renal prostaglandin
synthesis and diminish the antihypertensive effects of these
agents.25 The inhibition lessens afferent arteriolar flow and
causes a subsequent decrease in glomerular filtration rate,
especially in elderly patients. The use of NSAIDS and ACE
inhibitors in the elderly population has been found to be the
main cause of drug-induced acute renal failure.26 Sodium
depletion can also be a precipitating factor in renal failure,
therefore the use of diuretics and NSAIDS may also lead to
renal dysfunction.27 Lithium clearance can be decreased by
20% due to decreased prostaglandin production.25 Multiple
case reports have documented the relationship between
acute renal failure and the use of methotrexate and NSAIDS
simultaneously.28 When using one of these agents concurrently with NSAIDS, extra monitoring and vigilance may be
necessary to prevent lithium and methotrexate toxicity.

Pharmacokinetics
Ibuprofen is a racemic mixture of [-]R- and [+]S-isomers.25
The [+]S-isomer is responsible for clinical activity according

to in vivo and in vitro studies. The [-]R-isomer is slowly
and incompletely interconverted into the active [+]S-species
in adults. Active drug levels are maintained by circulating
reservoir of the [-]R-isomer. As described by early models
of the oral dosage form, ibuprofen best fits a linear or firstorder pharmacokinetic compartment model. Receipt of 5 to
10 mg/kg of oral ibuprofen suspension or solution results in
a time to achieve maximum concentration (tmax) of 0.75 to
1.5 hours.12,29,30 Elimination half-life is approximately 1.6
hours. The AUC of plasma ibuprofen is dose-dependent due to
the concentration-dependent protein binding where doubling
of the dose (5 to 10 mg/kg) results in a 1.6-fold increase in
drug exposure.29 Ibuprofen is highly protein bound (.99%
bound). The protein binding is saturable and at concentrations
.20 µg/mL becomes nonlinear. The estimated volume of distribution is 0.11 to 0.21 L/kg based on data from oral ibuprofen
and there is a known age- and fever-related change.29–32
The terminal half-life of intravenous ibuprofen appears
to be slightly above 2 hours (mean = 2.26 hours) and consistent across all dosing ranges.25 Similar to data from the oral
dosage form, antipyretic effects are delayed in relation to
peak concentrations and last longer despite declining plasma
ibuprofen concentrations. A summary of the pharmacokinetic
parameters of intravenous ibuprofen from initial studies are
detailed in Table 1. Important to note are the differences in
infusion time among the three studies summarized (5- to
7-minute rapid infusion, 30-minute infusion, and 60-minute
infusion).25,33,34 Infusion time greatly influences maximum
concentration (Cmax) and tmax, which is typically immediately
following the end of the infusion.

Table 1 Summary of pharmacokinetic parameters of intravenous ibuprofen
Parameter

100 mg dose

200 mg dose

400 mg dose

800 mg dose

Number of patients

31

30

31

_

AUC (μg.h/mL)

22.33 (12.75)

32.62 (17.39)

70.64 (31.93)

–

Cmax (μg/mL)

12.17 (6.78)

18.93 (10.50)

39.76 (17.75)

–

T1/2 (h)

2.47 (1.15)

2.11 (1.05)

2.26 (0.95)

–

12

12

Study: Morris et al33

Study: Intravenous ibuprofen product labeling; Data on file with Cumberland Pharmaceuticals® 25,34
Number of patients

–

–

AUC (μg.h/mL)

–

–

109.3 (26.4)

192.8 (18.5)

Cmax (μg/mL)

–

–

39.2 (15.5)

72.6 (13.2)

T1/2 (h)

–

–

2.22 (20.1)

2.44 (12.9)

–

–

–

12

Study: Pavliv et al34
Number of patients
AUC (μg.h/mL)

–

–

–

195.7 (37.3)

Cmax (μg/mL)

–

–

–

120.3 (13.5)

T1/2 (h)

–

–

–

2.0 (0.5)
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In a pharmacokinetic study of 24 healthy volunteers, doses
of 400 mg and 800 mg were administered over 60-minute
infusions.25 The association between the different doses
demonstrates a Cmax ratio of 1.7 and an AUC ratio of 1.8 for
the 400 mg and 800 mg doses, respectively.25 These data are
similar to the pharmacokinetics observed with oral ibuprofen.
Unpublished data of a randomized, cross-over, placebo controlled study, examined the pharmacokinetic profile of an
800-mg dose given via rapid infusion over 5 to 7 minutes.34
Twelve healthy volunteers, mean age of 31.7 years and
mean weight of 77 kg, were enrolled. At approximately
three hours post-dose, the mean serum concentration
was 20 µg/mL with a half-life of approximately 2 hours.
The AUCt-inf of 196 µg⋅h/mL (±37) is similar to previous
pharmacokinetic studies in subjects receiving 800 mg.
Compared to oral dosing of 800 mg in the same population,
the AUCs were very similar (196.4 vs 195.7), but Cmax nearly
doubled (120.3 vs 62.8) with significantly shorter time to
peak concentrations (6.5 vs 90 minutes).
In a multi-center, randomized, double-blind, placebocontrolled trial conducted by Morris et al 120 hospitalized
patients (88 men, 32 women) with temperatures of 38.3°C or
greater were randomized to intravenous ibuprofen 400 mg,
200 mg, 100 mg or placebo, administered every 4 hours for
24 hours over a 30-minute infusion.33 Both first-dose and
steady state kinetics were evaluated in all 3 dosing arms. Of
note, 44% of these patients were critically ill and all patients
were febrile. At all evaluable time points, mean ibuprofen
concentrations were significantly lower in critically ill
subjects compared to non-critically ill. Although the influence of fever specifically within these subgroups cannot be
evaluated, changes in volume of distribution in a critically ill
patient may influence the lower Cmax and AUC. For dosing,
this may implicate the need for higher than 400 mg doses
in critically ill populations if desired clinical response is not
achieved. Data regarding the clinical outcomes of this study
are detailed in later sections. Clinically, 800 mg doses have
proven effective in a critically ill burn population, however
the pharmacokinetic profiles have not been reported.35

Pediatrics
Specific studies of the intravenous ibuprofen formulation
have not been conducted in pediatrics. Pharmacokinetic
analyses in febrile children receiving oral ibuprofen demonstrated obtainment of peak concentrations 0.75 to 1.5 hours
following oral dosages of 5 to 10 mg/kg.12,29,30,36 Volume
of distribution was similar to that found in adults, 0.16 to
0.18 L/kg. Although oral absorption from the gastrointestinal
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tract was complete, there was a delay in maximum antipyretic
effects up to 2.5 hours following achievement of peak
concentrations.
Age-related phenomena have been well described with
ibuprofen. Wilson et al demonstrated a difference in antipyretic response in children .6 years of age compared to
those #6 years old, with no apparent differences in pharmacokinetic properties.36 These same investigators also reported
pharmacokinetic differences in younger children (,2.5 years
of age) where an increased ibuprofen clearance was observed
compared to older children, likely due to a larger volume of
distribution.29
Also, consistent with product labeling of oral ibuprofen
products, children with a temperature .39.2°C, a dosage
increase to 10 mg/kg is recommended to compensate for the
reduced antipyretic effect. Kauffman et al observed a faster
onset and greater antipyretic effect in children ,1 years of
age, compared to those .6 years old.12 This was independent
of any significant differences in pharmacokinetic properties.
Data using alternative formulations of intravenous ibuprofen
in special populations of pediatrics are described below
regarding cerebrospinal fluid (CSF) penetration and use
in cystic fibrosis patients. Although, there are no current
recommendations for intravenous ibuprofen in pediatrics,
the rapid achievement of peak concentrations could prove
clinically beneficial when timely antipyretic effects are
desired.

Central nervous system
A single pharmacokinetic study in pediatrics investigated
the CSF and plasma concentrations of intravenous ibuprofen
(Ibuprof von ct. Germany) in children following inguinal
surgery.37 Thirty-six children, aged 3 months to 12 years
(median 40 months) received a single intravenous injection
of ibuprofen (10 mg/kg). CSF concentrations ranged between
15 and 541 µg/L, with the peak concentrations measured 30
to 38 minutes after dosing. At the onset of post-surgical pain,
186 to 266 minutes following ibuprofen injection, the correlating plasma concentrations ranged between 10 and 25 mg/L
(median 21 mg/L). Ibuprofen was over 99% protein bound,
with a median unbound/total plasma concentrations ratio
of 0.0020. All ibuprofen CSF concentrations exceeded that
of unbound plasma concentrations in all samples collected
30 minutes post-dose. These results suggest a rapid movement of drug into the CSF and sustained plasma analgesic
concentrations for 2 to 4 hours following a single 10 mg/
kg dose in pediatrics undergoing inguinal surgery. A study
examining CSF concentrations in adults receiving a single
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800 mg oral dose demonstrated a similar peak CSF concentration, obtained at 3 hours as opposed to 30 minutes following
intravenous administration.38 In patients undergoing similar
short-term recovery or outpatient surgeries, this correlates
well to being able to provide the patient with a second dose
or discharge dose 3 to 4 hours post surgery.
Penetration into the CSF is governed partially by the lipophilicity of the agent. Ibuprofen, similar to other NSAIDS,
is lipophilic, and thus possesses the ability to readily cross
the blood–brain and blood–CSF barriers. At physiologic pH
(7.4), the apparent partition coefficient is 1.1, which suggests ready diffusion into the CSF; however, ibuprofen is
almost totally ionized at these conditions (99%), restricting
movement into the CNS.39 The highly protein bound nature
of ibuprofen may limit its movement across the blood–CSF
and blood–brain barrier, as only unbound drug can readily
diffuse. Additional mechanisms have been suggested to
limit diffusion such as efflux mechanisms at the blood–CSF
barrier including multidrug resistance proteins and organic
anion transport systems.40–42 By comparison to ketoprofen
and indomethacin, ibuprofen seems to more readily cross
into the CNS, with less interpatient variability.43,44

Cystic fibrosis
As with many drugs, cystic fibrosis (CF) patients appear to
exhibit altered pharmacokinetics of ibuprofen in comparison
to healthy controls. The primary pharmacokinetic alterations
in CF patients include reduced absorption, increased volume
of distribution, and more rapid clearance.45 The reduction
in absorption of oral ibuprofen encountered in patients with
CF leads to a reduction in Cmax and AUC of 27% and 46%,
respectively, compared to healthy children.46 Although no
data exist with the intravenous formulation specifically in
this population, this route of administration may be particularly advantageous in avoiding the interpatient variability
and reduced absorption encountered with alternative routes
of administration.

Dosage and administration
The lowest effective dose should be used for the shortest
duration consistent with individual patient treatment goals.
The maximum daily dose is 3200 mg.25 Patients should be
hydrated prior to administration of intravenous ibuprofen
to reduce the risk of renal adverse reactions. For analgesia,
400 mg to 800 mg should be administered intravenously every
6 hours as necessary. For fever 400 mg intravenously followed by 400 mg every 4 to 6 hours or 100 to 200 mg every
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4 hours should be administered as necessary. According to the
product labeling, the minimum infusion time for intravenous
ibuprofen is 30 minutes. A randomized, cross-over, placebo
controlled study, examined the safety and tolerability of a
single 800-mg dose given via rapid infusion over 5 to 7 minutes in 12 healthy volunteers, and 4 of 12 subjects reported
infusion-related site pain.34 Rapid infusion, when tolerated,
may be pragmatic in the post-operative or intensive care unit
setting resulting in rapid achievement of Cmax (see Pharmacokinetics section), also aiding in administration decisions at
the patient’s bedside. Intravenous ibuprofen is available as a
400 mg/4 mL single-dose vial and 800 mg/8 mL single-dose
vial.25 The stopper in the intravenous ibuprofen vial does not
contain natural rubber latex, drug natural rubber, or blends
of natural rubber.

Drug formulation
Ibuprofen, (±)-2-(p-isobutylphenyl) propionic acid, is the
active ingredient in intravenous ibuprofen (Caldolor ®).25
Arginine is also contained in this product to assist with
stability at a molar ratio of 0.92:1 of arginine:ibuprofen.
Ibuprofen is soluble in agents such as acetone and ethanol,
but only slightly soluble in water (,1 mg/mL). To prevent
serious phlebitis during administration, the final concentration during admixture must be 4 mg/mL or less. Intravenous
ibuprofen is stable when 0.9% sodium chloride injection
USP (normal saline), 5% dextrose injection USP (D5W), or
lactated Ringer’s solution is used as the diluent.47 Intravenous
ibuprofen is available as a 400 mg/4 mL single-dose vial and
800 mg/8 mL single-dose vial. Once diluted, intravenous
ibuprofen remains stable for 7 days at room temperature in
standard lighting.

Clinical evaluation
Results from an increasing number of clinical studies demonstrate an interesting analgesic and antipyretic profile of
intravenous ibuprofen in the management of mild to moderate
pain, management of moderate to severe pain as an adjunct
to opioid analgesics, and reduction of fever. Studies are
reviewed based on their clinical indication.

Use in post-operative pain
Three randomized, double-blind, placebo-controlled trials
of intravenous ibuprofen to evaluate the safety and efficacy
as a post-operative analgesic have been published to date.
The first examined the effects of intravenously administered
ibuprofen 400 and 800 mg every 6 hours in post-operative
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pain management.3 Subjects were recruited through 17 sites
within the United States, Australia, and the Republic of South
Africa between February 2005 and September 2006. Subjects
were scheduled to undergo elective, single-site orthopedic
or abdominal surgery and were expected to require hospitalization and postoperative analgesia with intravenously
administered morphine for .14 hours after surgery. After
surgery, all patients received morphine by hospital staff on
patient request or patient-controlled analgesia (PCA) pump
(1 to 2 mg every 5 minutes) and were assigned in a 1:1:1 ratio
using a stratified, blinded by site, randomization scheme to
receive ibuprofen 400 mg intravenous, ibuprofen 800 mg
intravenous, or inactive vehicle (placebo), every 6 hours
for a total of 8 doses, over the first 48 hours of the study.
After the initial 8 doses, the protocol allowed for continued
administration of intravenous ibuprofen or placebo every
6 hours, at the discretion of the investigator, for control of
postoperative pain for a total of up to 120 hours (5 days). The
primary outcome measure was the mean amount of morphine
administered during the first 24 hours following surgery. Statistical analyses of the efficacy end points were conducted on
the intent-to-treat (ITT) population and the efficacy-evaluable
(EE) population (all patients who received at least 4 doses of
intravenous ibuprofen or placebo within 60 minutes of the
scheduled administration time). A total of 406 patients were
enrolled and were all included in the ITT population, and a
total of 342 patients who received the first 4 doses of study
medication were included in the EE population. In the ITT
population, median morphine use was significantly reduced
during the first 24 hours of administration of study drug in
patients who received ibuprofen 800 mg intravenous every
6 hours by 22% vs placebo (P = 0.030); the difference in
morphine use between the ibuprofen 400 mg intravenous
and placebo groups was not significant.
In a second multi-center, randomized, double-blind,
placebo-controlled trial, women who had undergone an elective abdominal hysterectomy, were randomized and treated
with intravenous ibuprofen 800 mg or placebo administered
every 6 hours started intra-operatively.48,49 Subjects also
received morphine administered on an as needed basis. Efficacy was demonstrated by measuring the patients’ morphine
usage during the post-operative period and self assessment of
pain at rest and with movement using a visual analog scale
(VAS). The study found that patients receiving 800 mg of
intravenous ibuprofen had 19% less median morphine use.
Subjects receiving intravenous ibuprofen had a 21% and
14% reduction in pain intensity on the VAS at rest and with
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movement, respectively. The median morphine usage is summarized in Table 2.
In a third multi-center, randomized, double-blind,
placebo-controlled trial, a total of 185 patients undergoing elective knee or hip orthopedic surgery were randomly
assigned in 1:1 ratio to receive either 800 mg intravenous
ibuprofen or placebo every 6 hours.50 In addition, all patients
had access to morphine, and the first dose of study medication
was administered prior to surgery. Efficacy was demonstrated
by measuring the patients’ self-assessment of pain with
movement and at rest using a VAS and a verbal response
scale (VRS). Morphine use during the post-operative period
was also compared between groups as an efficacy measure.
Patients receiving 800 mg intravenous ibuprofen compared
to placebo experienced a significant reduction in pain as measured by the area under the curve of the VAS (VAS-AUC)
with movement and at rest for the post-operative period, study
hours 6 to 28 (P , 0.001). There was a 25.8% reduction in
mean VAS-AUC (with movement) (P , 0.001) and a 30.9%
reduction in morphine usage (P , 0.001) in patients receiving intravenous ibuprofen. There was a 31.8% reduction in
mean VAS-AUC (at rest) and a 20.2% reduction in mean
VRS in patients receiving intravenous ibuprofen. There was
not a significant difference in the number of adverse events
observed between the treatment groups.

Use for fever
Morris et al investigated intravenous ibuprofen to reduce
fever.33 One hundred twenty hospitalized adult patients at
nine sites (88 men, 32 women) with temperatures of 38.3°C
or greater were randomized to intravenous ibuprofen 400 mg,
200 mg, 100 mg or placebo, administered every 4 hours for
24 hours. Fifty-three of the 120 patients (44%) were critically
ill and receiving mechanical ventilation and/or vasopressor
support. The primary objective was to evaluate the efficacy
of 400 mg intravenous ibuprofen on reducing fever to greater
than or equal to 38.3°C, determined by the percentage of
subjects with temperature less than 38.3°C at 4 hours after
administration of a single dose, as compared with the efficacy
of parallel placebo treatment. Each of the three intravenous
ibuprofen doses, 100 mg, 200 mg, and 400 mg, resulted in a
statistically greater percentage of patients with a reduced temperature (,3) after 4 hours, compared to placebo (61%, 70%,
77% and 32%, respectively). Temperature decreased in both
the critically ill and non-critically ill subjects receiving intravenous ibuprofen versus those receiving placebo. However,
this study was not designed to show differences in efficacy
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Table 2 Summary of intravenous ibuprofen clinical studies
Author

Study aim

Treatment arm

Results

Kroll et al

Efficacy and safety in adult
abdominal surgery patients
(N = 319)

800 mg IV or placebo every
6 hours + PRN morphine

Efficacy: morphine requirements in
ibuprofen group 43.7 mg and placebo
56 mg (P , 0.001)
Safety: no differences in adverse events

NCT00606489,
Cumberland
Pharmaceuticals, Inc.56

Efficacy (fever and pain) and
safety in pediatric and adult burn
patients (N = 61)

800 mg IV or placebo every
6 hours during 120-hour
treatment period

Efficacy: significant reduction in fever in
800 mg ibuprofen versus placebo in first
24 hours as measured by AUC-T (P = 0.03)
Safety: no significant difference between
the two groups for adverse events; no
differences between the groups for
laboratory values, frequency of blood
transfusions, or bleeding

Morris et al33

Efficacy (fever) and safety in
hospitalized adult patients
(N = 120; ∼33% were critically illa)

100 mg, 200 mg, 400 mg IV
or placebo every 4 hours
for a total of 6 doses

Efficacy: proportion of patients ,38.3°C
at 4 hours post initial dose: placebo
(32%), 100 mg (61%), 200 mg (70%),
400 mg (77%) (P , 0.05 for all
treatment arms versus placebo)
Safety: no statistical significant differences
in serious adverse events between
treatment arms through study day 28

NCT00470600,
Cumberland
Pharmaceuticals, Inc.50

Efficacy and safety in hospitalized
adult orthopedic surgery patients
(N = 185)

800 mg IV or placebo every
6 hours + PRN morphine

Efficacy: morphine requirements
reduced by 30.9% compared to placebo
(P , 0.001); reduction of 20%–32%
in mean VAS-AUC (at movement
and rest) and VRS;
Safety: significant increase in vomiting in
the treatment arm versus placebo

Southworth et al3

Efficacy and safety in adult
abdominal (73%) or orthopedic
surgery patients (27%) (N = 406)

400 mg, 800 mg IV or
placebo every 6 hours for
8 doses + morphine PCA

Efficacy: morphine requirements reduced
by 22% in the 800 mg arm (P = 0.03),
3% in the 400 mg arm (P = NS) versus
placebo; 800 mg arm resulted in significant
reductions in pain earlier than 400 mg arm
when compared to placebo (1–6 hours
versus 6–12 hours)
Safety: no significant differences in serious
adverse events between treatment arms
through study day 14

49

a
Critically ill defined as mechanical ventilation and/or requiring vasopressor support.
Abbreviations: IV, intravenous; PRN, as needed; AUC-T, area under the temperature curve; VAS, visual analog scale; VRS, verbal response scale; PCA, patient-controlled
analgesia.

between treatment doses. This study may demonstrate that
higher doses, such as 800 mg are required for fever reduction
in critically ill patients.
The antipyretic effects have also been demonstrated in
a critically ill burn population.35,51 Patients in this randomized, double-blind, placebo-controlled trial were enrolled
from 5 burn centers or units both domestic and international.
A total of 61 adult patients with second- or third-degree burns
over at least 10% body surface area were included. Patients
received either placebo or 800 mg intravenous ibuprofen
every 6 hours for 5 consecutive days. Significant reductions
in fever curve were noted in the first 24 hours.
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Use in arrhythmias
Threatening arrhythmias were suppressed following the
administration of intravenous ibuprofen during electrical storm.52
In 4 patients admitted with a diagnosis of cardiomyopathy and
atrioventricular block secondary to an acute ischemic insult, lifethreatening ventricular tachyarrhythmias responded to a single
intravenous 400 mg dose of ibuprofen. In each case, the arrhythmias were refractory to amiodarone treatment. This is the first
report of suppression of arrhythmias through the administration
of an anti-inflammatory medication. Although, this provides
some evidence for ibuprofen in arrhythmias, more data on its
use for this purpose are needed before widespread use.
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Use in pediatrics
Currently the use as an analgesic in pediatrics is limited to
a pharmacokinetic study not designed to evaluate efficacy.37
As described above, 36 children received a single 10 mg/kg
dose of intravenous ibuprofen over 5-minute rapid infusion
prior to surgery using spinal anesthesia. Additionally, most
children were premedicated with midazolam and ketamine
prior to receiving bupivicaine for spinal anesthesia. The
median time to pain after surgery was 138 minutes (range 57
to 231 minutes) and after ibuprofen injection was 213 minutes
(range of 186 to 266 minutes). Three children received a second dose of ibuprofen in the post-anesthesia care unit, while
25 received ketoprofen. Ten children reported severe pain
defined as .3/10 at rest or .5/10 with 20-N compression post
surgery that required opioid rescue. Data using intravenous
ibuprofen in burn patients included pediatric and adult patients.
However, pediatric specific data are not available.35
Additional data in pediatrics focuses on infantile use in
patent ductus arteriosus with alternative intravenous ibuprofen products. These data are not reviewed here.53–55

Safety and tolerability
Post-operative patients
Southworth and colleagues determined that 91% (368/406)
of patients experienced treatment-emergent adverse events
when comparing morphine PCA combined with 400 mg
or 800 mg of intravenous ibuprofen or placebo.3 Nausea,
vomiting, and constipation occurred most frequently in
all study arms including placebo with fewer side effects
observed with ibuprofen. There was significantly less nausea
with 400 mg ibuprofen relative to placebo. This apparent
reduction in gastrointestinal side effects is likely related to
a reduction in opioid use and a corresponding reduction in
their adverse effects. Pyrexia was also significantly reduced
in the 400 mg and 800 mg ibuprofen arms as compared to
placebo. In the 800 mg ibuprofen arm, a statistical reduction was found in the incidence of dizziness as compared
to placebo. Laboratory values including renal function and
vital sign measurements were similar throughout the study
in all three groups. The incidence of bleeding and bruising
did not differ significantly between the groups. Overall, the
total blood units transfused during the study were similar
amongst all three arms. Of the 406 patients treated in this
study, there were no deaths reported. Discontinuation of
the study drug occurred on day 5 of 14 for all 406 patients.
Most of these patients were able to tolerate oral pain medication on day 5, and therefore the intravenous therapy was
discontinued.
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In 319 female patients undergoing elective abdominal
hysterectomy, randomized to receive 800 mg intravenous
ibuprofen every 6 hours or placebo, there were no differences
in treatment-emergent adverse events.48,49 Clinical laboratory
assessments including renal and hepatic function were similar
between the two groups and the most common side effects
were similar to those associated with oral ibuprofen use.
Serious adverse effects were determined to be related to the
hysterectomy procedure itself, and not study drug. Similar
results were found in the 185 patients undergoing orthopedic
elective knee or hip surgery, with the exception of a difference
in gastrointestinal side effects. There were significantly more
patients who experienced emesis in the ibuprofen group as
compared to placebo, however significantly more patients in
the placebo group reported dyspepsia.
A study of hospitalized burn patients found no significant differences between the group treated with intravenous
ibuprofen 800 mg and placebo.51,56 No significant differences
in the incidences leucocytosis and anemia were found. Five
subjects experienced 6 serious adverse events in the ibuprofen
group and 3 subjects experienced 6 adverse events in the placebo group. There was no difference in the clinical laboratory
assessments (serum creatinine levels, hemoglobin, platelet
counts, prothrombin time, or activated partial thromboplastin time) between the two groups. The frequency of blood
transfusions was similar in both groups. Findings from this
study were similar to previous studies and demonstrated a
relatively favorable side effect profile.

Critically ill patients
Morris and colleagues evaluated the safety and efficacy
of intravenous ibuprofen in 120 hospitalized adult febrile
patients.33 Between the 100 mg, 200 mg, and 400 mg arms of
intravenous ibuprofen as compared to placebo, there were no
statistically significant differences when comparing the three
groups except for the incidence of bacteremia. In the 100 mg
intravenous ibuprofen group, there were 4 cases of bacteremia
(13%) as compared to 0% in the placebo group. Since this
increase was not observed in any other ibuprofen arms, it is
unlikely that these events were associated with the study drug
as this side effect. Like the previous studies, there were no
differences found between the three groups in terms of serious adverse events, bleeding or bruising, laboratory values,
hemoglobin/hematocrit values, or transfusion requirements.

Bleeding
One of the major concerns in using intravenous ibuprofen
in the acute care setting is the risk of bleeding. In a 30-day
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prospective, phase III, randomized, placebo-controlled,
double-blind study that enrolled 450 patients with severe
sepsis syndrome, intravenous ibuprofen was administered to
determine the efficacy and safety of intravenous ibuprofen in
reducing mortality.23 Patients received 10 mg/kg of intravenous ibuprofen every 6 hours times 8 doses for a maximum
infusion of 6400 mg intravenous or placebo after diagnosis
of sepsis syndrome. Evaluation of bleeding events, tranfusion requirements, and serial laboratory measurements were
documented (hemoglobin, hematocrit, platelets, pro-thrombin
time, and activated partial thromboplastin time) at baseline
and 0, 20, 44, 72, 96, and 120 hours after initiation of therapy.
There were 15 events in the ibuprofen arm and 25 events in
the placebo arm that could be classified as bleeding complications Of the 40 total bleeding events, the majority of
these were related to gastrointestinal bleeding (19 placebo,
9 ibuprofen). Two patients in the placebo arm experienced a
cerebrovascular accident compared to 3 patients in the ibuprofen arm. One patient in the ibuprofen arm experienced a
pulmonary hemorrhage. At baseline, 117 patients received
transfusions with an additional 146 in the placebo group and
153 in the ibuprofen group receiving transfusions at the onset
of dosing through 120 hours. Administration of total blood
products including packed red blood cells, platelets, fresh
frozen plasma and albumin were similar between the two
groups. In the ibuprofen group, the average units transfused
per patient was 3.66 ± 0.33 units versus 3.34 ± 0.26 units in the
placebo group. Of the laboratory values assessed for bleeding,
no statistical differences between the groups were observed
at any time point (P . 0.05). Overall, patients treated with
intravenous ibuprofen in the setting of sepsis syndrome where
the bleeding risk is extremely high, there were no differences
in bleeding events, transfusion requirements, or coagulation
abnormalities.

Infusion-related reactions
According to the package insert, intravenous ibuprofen infusion time should be no less than 30 minutes due to concerns
of infusion related reactions.25 In a pharmacokinetics study
conducted by Pavliv, 12 healthy patients were administered
800 mg of intravenous ibuprofen over 5 to 7 minutes + oral
placebo followed by a 7-day washout period when they
received 800 mg of ibuprofen + placebo intravenous ibuprofen
over 5 to 7 minutes.34 The objective of this study was to evaluate the pharmacokinetic profile and safety and tolerability
of administering rapid infusion intravenous ibuprofen. The
intravenous ibuprofen formulation was considered equivalent
to the oral therapy. More importantly, minor infusion related
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reactions were documented. Four patients experienced pain
upon infusion while no patients experienced burning while
receiving intravenous ibuprofen. All four of the adverse events
resolved and no subsequent changes in vital signs were noted.
Therefore, intravenous ibuprofen may be administered safety
over 5 to 7 minutes if needed with minimal infusion related
adverse effects.

Invasive group A streptococcal infections
The use of NSAIDS has been associated with invasive group
A beta-hemolytic streptococcal infections including necrotizing skin and soft tissue infections.57–59 Associations have been
strongest in pediatric patients and those with a previous varicella infection.60,61 Determination of a true causal relationship
is difficult for several reasons including the ubiquitous use of
NSAIDs, inherent limitations of the retrospective study design,
and overall relatively low incidence of necrotizing GAS
infections. NSAID therapy may delay diagnosis of invasive
infections when used for antipyretic and analgesic effects early
in the disease process.57–59 Alternatively, COX inhibition may
blunt the immune response and decrease leukocyte activity and
endothelial interactions at the site of infection.62,63

Bone effects
Several studies have proven that nonspecific NSAIDS may
inhibit new bone growth and interrupt fracture healing.64,65
Recently, Goodman and colleagues conducted a study in
rabbits comparing a non-specific COX-1 and COX-2 inhibitor, and a specific COX-2 inhibitor to determine differences
in bone ingrowth and tissue differentiation.66 By using a
titanium implant, or harvest chamber, researchers were able
to monitor new bone growth in New Zealand white rabbits
after administration of NSAIDS. The researchers found
that when administered naproxen (non-specific COX-1 and
COX-2 inhibitor), tissue bone ingrowth decreased by 15.9%
versus 18.5% with the rofecoxib (selective COX-2 inhibitor).
Although these results were not statistically significant, the
authors concluded that bone ingrowth or fracture healing may
be delayed when agents with COX-2 inhibitory properties are
used. Because the bone healing of rabbit is very similar to
humans, these data can be applicable. The authors concluded
that patients should not take COX-2 inhibitors for at least
6 weeks following a fracture or implant procedure, although
the duration of effect is still currently under research.

Summary of safety and tolerability
Overall data indicate a similar safety and tolerability profile
with intravenous and oral ibuprofen.
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Cardiovascular thrombotic events, gastrointestinal
effects, bleeding, hypertension, renal effects, anaphylactoid
reactions, and bronchospasm have all been observed with
oral ibuprofen therapy. Many of these side effects were not
observed in studies of intravenous ibuprofen, but are still possible. The short study durations and inclusion of patients with
few co morbidities reduced the likelihood of these adverse
events during studies of intravenous ibuprofen. In addition,
the longer duration of oral ibuprofen therapy is a likely contributor to the cardiovascular thrombotic effects, bleeding
events, and renal effects. The potential for cardiovascular
thrombotic events make ibuprofen a less desirable option for
post-operative pain secondary to cardiac or vascular surgery
procedures. In addition, although no adverse effects on renal
function were observed in trials of intravenous ibuprofen
it should be used with caution in patients with underlying
renal disease. Patients with a history of bleeding also may
be poor candidates for therapy with intravenous ibuprofen,
and patients with a history of GI bleeding should not receive
intravenous ibuprofen. These patients were excluded from
clinical trials and an increased risk of bleeding was not
observed. However, the GI side effects from ibuprofen arise
from both topical injury and COX-1 inhibition, which is
present even when a parenteral formulation is used.67 For
reasons detailed above, although most of these side effects
are not experienced in trials of intravenous ibuprofen, the
manufacturer still details these precautions for the intravenous formulation.

Summary and recommendations
Intravenous ibuprofen is an attractive option for the treatment of pain in the acute post-operative setting and for use
in the critically ill population. Data in a relatively small
number of patients demonstrate its efficacy in reducing
opioid requirements and pain scores relative to placebo in
a variety of post-operative settings including abdominal
and orthopedic procedures. In addition, data support its
efficacy in reducing fever in the acute and critical care
settings. Doses of 400 to 800 mg are recommended for
both analgesic and antipyretic effects in these settings.
In the critically ill population, higher single doses of 800
mg should be considered to maximize desired effects.
Although a 30-minute infusion is recommended, data on
the safe use of a rapid infusion of 5 to 7 minutes are encouraging for ease of administration and optimizing rapid
onset. Recognition of injection site pain with intravenous
administration is important, specifically when employing
a rapid infusion.
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Although chronic or long-term therapy is not likely with
the intravenous dosage form, extended use in the hospitalized
patient should be anticipated. Extra caution and monitoring
are required in patients for extended use and those with significant co-morbidities, including those undergoing cardiac
or vascular procedures. Post-marketing surveillance will be
critical as intravenous ibuprofen becomes more widely used.
Current studies include relatively small numbers of patients,
making differences in adverse events difficult to detect. They
also followed patients for relatively short periods of time,
and toxicities are more likely to be seen with prolonged
therapy.67 At this time, intravenous ibuprofen appears to be
a useful adjunct for short-term use in post-operative pain
in adult patients without significant underlying disease
states and for potential use in critically ill patients for desired
antipyresis.
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